◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › OCS

Oculis Holding AG (OCS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-20

Oculis Holding AG (OCS) operates in the Biotechnology industry and is headquartered in Zug, Switzerland with about 60 employees. Its market capitalization is roughly $736 million. In the fiscal year ended 2025-12-31, OCS reported $0M in revenue and ($99M) in net income.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.

Interactive charts & full statements → Open the OCS valuation workbench →

OCS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($82M)($73M)($46M)($32M)
Net Income($99M)($86M)($89M)($39M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($22M)($21M)($20M)($21M)($20M)
Net Income($29M)($24M)($17M)($25M)($33M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Free Cash Flow History

Cash flow2025-12-312024-12-312023-12-312022-12-312021-12-31
Dividends Paid$0M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Dividends Paid$0M$0M$0M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

OCS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$236M$120M$114M$37M
Total Liabilities$40M$47M$21M$135M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OCS viewer.

Other Companies in Biotechnology

← OCGNAll stocksOCSL →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.